

# Industry Insight

## INDIAN PHARMACEUTICALS

April 2007

---

# Cygnus

Business Consulting & Research

*Knowledge Partner For Profitable Growth*

4<sup>th</sup> & 5<sup>th</sup> Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India

Tel: +91-40-23430303-05, Fax: +91-40-23430201, E-mail: [info@cygnusindia.com](mailto:info@cygnusindia.com)

Website: [www.cygnusindia.com](http://www.cygnusindia.com)

**Disclaimer:** All information contained in this report has been obtained from sources believed to be accurate by **Cygnus Business Consulting & Research** (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

# CONTENTS

1. EXECUTIVE SUMMARY .....	7
2. HIGHLIGHTS.....	10
3. INDUSTRY OVERVIEW .....	12
3.1 Indian Pharmaceutical Industry .....	12
3.2 Pharmaceutical Market Size .....	12
3.3 Industry Segmentation .....	13
3.4 Major Players .....	14
3.5 Major Exporters .....	18
3.6 Demand-supply analysis .....	20
3.7 Foreign Direct Investments in Indian Pharma.....	21
4. GROWTH DRIVERS .....	22
4.1 Global Growth Drivers .....	22
4.1.1 Innovation of Biotechnology.....	22
4.1.2 Demographic Transition .....	23
4.1.3 Rising real incomes .....	23
4.1.4 Medical technology.....	24
4.1.5 Generic and niche segments .....	24
4.1.6 Unmet medical needs .....	24
4.2 Indian Pharma .....	25
4.2.1 Ageing Population .....	25
4.2.2 Life Style Drugs .....	25
4.2.3 Healthcare Expenditure .....	26
4.2.4 Upgradation of Medical Devices & Equipment.....	26
4.2.5 Export.....	27
4.2.6 Generic Drugs .....	27
4.2.7 Research & Development .....	27
4.2.8 Contract Manufacturing Opportunities .....	28
5. ISSUES & CHALLENGES .....	29
5.1 Sustaining exports .....	29
5.2 IPR issues.....	30

5.2.1 Pricing .....	31
5.2.2 Central excise on MRP of medicines .....	31
5.2.3 Data protection.....	31
5.3 R&D focus .....	32
5.3.1 Looming shortage of trained manpower.....	33
5.3.2 Animal trials.....	33
5.3.3 Regulatory Infrastructure.....	33
5.3.4 Managing productivity .....	34
5.4 Exploiting generic opportunities.....	34
5.5 Price control .....	34
5.6 Infrastructure.....	35
5.6.1 R&D Infrastructure.....	35
5.6.2 Quality of marketing infrastructure .....	35
5.7 Fragmentation .....	35
5.8 Spurious drugs.....	36
6. MAJOR PLAYERS .....	37
6.1 Ranbaxy Laboratories Ltd.....	38
6.2 Cipla Ltd. ....	43
6.3 Dr. Reddy's Laboratories Ltd. ....	47
6.4 LUPIN LTD. ....	52
6.5 Glaxo SmithKline Pharmaceuticals Ltd.....	56
6.6 Nicholas Piramal India Ltd. ....	60
6.7 Aurobindo Pharma Ltd. ....	64
6.8 Sun Pharmaceutical Industries Ltd. ....	68
6.9 Cadila Healthcare Ltd.....	74
6.10 Wockhardt Ltd. ....	79
6.11 Aventis Pharma Ltd.....	83
6.12 Orchid Chemicals and Pharmaceuticals Ltd. ....	87
6.13 IPCA Laboratoaries Ltd. ....	91
6.14 Atul Limited .....	96
6.15 Torrent Pharmaceuticals Limited.....	100
6.16 Biocon Limited .....	104

6.17 Pfizer Ltd. ....	108
6.18 Sterling Biotech Ltd. ....	112
6.19 Matrix Laboratories Ltd. ....	116
6.20 Alembic Ltd. ....	120
<b>7. MAJOR SEGMENTS</b> .....	<b>125</b>
7.1 Bulk drugs .....	125
7.2 Formulations .....	126
<b>8. OUTSOURCING OPPORTUNITIES</b> .....	<b>129</b>
8.1 Factors driving outsourcing .....	130
8.1.1 Weaker pipelines and rising approval times.....	130
8.1.2 Pressure to cut prices .....	132
8.1.3 Declining market exclusivity period.....	132
8.1.4 Boosting marketing productivity .....	133
8.2 Outsourcing Market .....	134
8.2.1 Contract Manufacturing.....	135
8.2.2 Contract Research.....	137
<b>9. REGULATORY ISSUES</b> .....	<b>143</b>
9.1 Overview .....	143
9.2 Regulatory environment .....	143
9.2.1 General regulations .....	144
9.3 Entry strategies .....	145
9.3.1 Importing pharmaceuticals.....	146
9.3.2 Manufacturing under license.....	146
9.3.3 Entry through joint venture/subsidiary .....	146
9.3.4 Foreign Investment promotion board .....	147
9.3.5 Approvals for foreign companies with prior Indian exposure .....	147
9.3.6 Additional options .....	147
9.4 Key legislations .....	148
9.4.1 The drugs and cosmetics act, 1940 .....	148
9.4.2 The medicinal & toilet preparations act, 1955 with rules, 1956 .....	149
9.4.3 The drug policy, 1986.....	149
9.4.4 The essential commodities act, 1955 .....	149

9.4.5 Indian patents act, 1970 .....	149
9.4.6 The drugs price control order (DPCO), 1995.....	150
9.4.7 Good manufacturing practices .....	150
9.4.8 The pharmacy act, 1948 .....	150
9.5 Regulatory bodies .....	150
9.5.1 The drugs controller of India (DCI).....	150
9.5.2 State food and drug administrations (FDAS).....	151
9.5.3 National pharmaceutical pricing authority (NPPA).....	151
9.5.4 Department of chemicals and petrochemicals .....	151
9.6 Price controls .....	151
9.6.1 Pricing of scheduled bulk drugs.....	152
9.6.2 Pricing of scheduled formulations imported into India.....	152
9.6.3 Pricing regulations .....	152
9.7 Intellectual property rights .....	153
9.7.1 Legal procedure.....	154
9.7.2 Compulsory licensing and revocation of EMR .....	155
9.7.3 Permission for residents to apply for patents outside India .....	155
9.7.4 Trademarks .....	155
9.8 Manufacturing .....	156
9.8.1 Industrial licensing .....	157
9.8.2 Additional approvals/registration .....	157
9.8.3 Reservation for public sector .....	158
9.9 Imports.....	158
9.9.1 Imports of capital goods and raw materials.....	158
9.9.2 Pharmaceutical Imports .....	158
9.10 New drug approval process.....	159
9.10.1 Drug approval procedure .....	159
9.11 Product standards .....	160
9.11.1 Labeling.....	161
9.12 Tariff structure.....	162
9.12.1 Local manufacturing duty.....	162
9.12.2 Sales tax .....	162
9.13 Marketing and distribution.....	163

9.13.1 Licensing of sales outlets and stock holding .....	163
9.13.2 Prescription drugs .....	164
9.13.3 Advertisement and Promotion .....	164
9.13.4 Regulations of advertising.....	164
9.13.5 Packing and labeling .....	164
9.13.6 Distribution.....	165
9.13.7 Brands .....	165
9.13.8 Restrictive trade practices .....	165
9.12.9 Consumer protection.....	165
<b>10. CRITICAL SUCCESS FACTORS .....</b>	<b>167</b>
10.1 Research & Development .....	167
10.2 New product development .....	168
10.3 Therapeutic coverage .....	170
10.4 Marketing.....	171
10.5 Exports.....	171
10.6 Critical mass .....	172
10.7 Low cost production through scale .....	172
10.8 World class practices .....	173
10.9 Conclusion .....	173
<b>11. OUTLOOK.....</b>	<b>174</b>

## LIST OF CHARTS

- Chart 1: Indian pharmaceutical market (2001-2005) Chart 2: Therapeutic segments-2006
- Chart 3: FDI Investments in Pharmaceuticals 1993-2004
- Chart 4: Percentage of population above age of 64
- Chart 5: Value of products coming off patent 2005-08
- Chart 6: Projected Percentage of Age-wise Population Distribution
- Chart 7: Health-care Expenditure (2004-05)
- Chart 8: India's export of drugs, pharmaceuticals & fine chemicals
- Chart 9: Market forecast of contract manufacturing
- Chart 10: Export Trend
- Chart 11: Value of off Patenting Products
- Chart 12: USFDA Approved Plants
- Chart 13: Global outsourcing market size (US\$bn) Chart 14: New Molecular Entity Approvals
- Chart 15: Drug Development Period
- Chart 16: OTC Drugs & Nutritionals dominates CMO market Chart 17: OTC Drugs & nutritional to drive CMO market Chart 18: Indian pharmaceutical exports 1994-95 to 2004-05
- Chart 19: Global Clinical Trials Expected Growth Chart 20: Allocation of R&D Investments by Function Chart 21: Break up of clinical research market
- Chart 22: CRO Industry Analysis: 2004 Market (US\$bn) Chart 23: Clinical Spending in Ascending Regions
- Chart 24: Indian Clinical Trials Expected Growth

## LIST OF TABLES

- Table 1: Major brands in 2006
- Table 2: Revenue of top 10 pharmaceutical companies in India (Rs m)
- Table 3: India's Export of Drug, Pharmaceuticals & Fine Chemicals by Countries (US\$m) Table 4: Top 10 Exporters
- Table 5: Impact of patent protection
- Table 6: Top 20 players
- Table 7: DMF filings by Indian companies
- Table 8: Trend in Market Exclusivity Period
- Table 9: Leading Indian contract research organizations
- Table 10: Components of custom tariff
- Table 11: Tariffs on manufacturing